c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Oral oncology |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.sciencedirect.com/science/article/pii/S136883751630063X |
| Doi | http://dx.doi.org/10.1016/j.oraloncology.2016.05.017 |
| Field | Oncology and hematology |
| Keywords | squamous-cell carcinoma; randomized phase-ii; tivantinib arq 197; lung-cancer; acquired-resistance; metastatic head; plus erlotinib; double-blind; patients pts; placebo |
| Description | Mesenchymal–epithelial transition factor (c-MET), found on melanocytes, endothelial cells, and epithelial tissues, is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF), produced by elements of mesenchymal origin. The receptor-ligand pair controls diverse biological activities including cell proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis. |